Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2020-09-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether magnetic resonance imaging (MRI) using
inhaled hyperpolarized 129Xe gas, and conventional contrast can help visualize impaired lung
function and detect changes over time in patients receiving treatment as well as those who
don't. 129Xe is a special type of xenon gas and when inhaled during MRI may be able to show
areas of abnormal thickening of parts of the lungs. These images combined with images taken
with injected contrast agents or other types of MRI may provide a better way to look at lung
structure and function in patients with IPF. The ultimate goal is to predict how a particular
patient might respond to a particular therapy and to observe such responses earlier than
conventional tests. The investigators anticipate that the images acquired in this study will
provide more specific information about lung disease than standard lung function tests. The
use of 129Xe MRI is investigational. "Investigational" means that these tests have not yet
been approved by the US Food and Drug Administration and are being tested in research studies
like this one. In addition, standard MRI with contrast is not typically done as standard of
care for monitoring progression of IPF, therefore, its use in this study is also considered
investigational.
Healthy volunteers are being asked to participate in this study because the investigators
need to develop a database of functional images that are representative of healthy lungs.
Phase:
Phase 1
Details
Lead Sponsor:
Bastiaan Driehuys
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) University of Wisconsin, Madison